Most mutations in the rBAT subunit of the heterodimeric cystine transporter rBAT-b 0,1 AT cause type I cystinuria. Trafficking of the transporter requires the intracellular assembly of the two subunits. Without its partner, rBAT, but not b 0,1 AT, is rapidly degraded. We analyzed the initial biogenesis of wild-type rBAT and type I cystinuria rBAT mutants. rBAT was degraded, at least in part, via the ERAD pathway. Assembly with b 0,1 AT within the endoplasmic reticulum (ER) blocked rBAT degradation and could be independent of the calnexin chaperone system. This system was, however, necessary for post-assembly maturation of the heterodimer. Without b 0,1 AT, wild-type and rBAT mutants were degraded with similar kinetics. In its presence, rBAT mutants showed strongly reduced (L89P) or no transport activity, failed to acquire complex N-glycosylation and to oligomerize, suggesting assembly and/or folding defects. Most of the transmembrane domain mutant L89P did not heterodimerize with b 0,1 AT and was degraded. However, the few [L89P]rBATb 0,1 AT heterodimers were stable, consistent with assembly, but not folding, defects. Mutants of the rBAT extracellular domain (T216M, R365W, M467K and M467T) efficiently assembled with b 0,1 AT but were subsequently degraded. Together with earlier results, the data suggest a two-step biogenesis model, with the early assembly of the subunits followed by folding of the rBAT extracellular domain. Defects on either of these steps lead to the type I cystinuria phenotype.
INTRODUCTION
Cystinuria (OMIM 220100) is an autosomal recessive disease of renal reabsorption and intestinal absorption of cystine and dibasic amino acids. Cystine precipitates and forms calculi which ultimately produce renal insufficiency. Two cystinuria phenotypes are distinguished: type I, where the obligate heterozygotes have normal urinary excretion; and non-type I, where the obligate heterozygotes have moderate to high excess of urinary excretion of cystine and dibasic amino acids (1) . All but one mutations in SLC3A1, encoding rBAT, cause type I cystinuria (2, 3) . Mutations in SLC7A9, encoding b 0,þ AT, cause non-type I phenotype and also some type I cases (3) . A gene dosage effect can explain non-type I cystinuria, since SLC7A9 þ/2 mice express already the phenotype (4). It is not known why type I heterozygotes are silent.
rBAT is a type II membrane glycoprotein with a large glucosidase-like extracellular domain. b 0,þ AT is a nonglycosylated, polytopic membrane protein. Their co-expression induces the transport system b 0,þ -like, an obligatory exchanger that physiologically mediates the influx of cystine and dibasic amino acids and the efflux of neutral amino acids (5, 6) . Intracellular assembly of rBAT with b 0,þ AT to form a disulfide-linked heterodimer is required for functional expression. When expressed alone, rBAT remains endoglycosidase H sensitive and is degraded, whereas b 0,þ AT is stable (7, 8) . In contrast, b 0,þ AT expressed alone is stable and can be recovered in a functional form from its intracellular location (7 -9) . The rBAT-b 0,þ AT heterodimer oligomerizes into a stable heterotetramer expressed in the brush border membranes of the epithelial cells of the renal proximal † M.P. and J.C. share last authorship.
tubule (10) . System b 0,þ -like is the main apical reabsorption system for cystine in kidney (6) .
From the more than 60 rBAT mutations found in type I cystinuria patients, all are located in the extracellular domain, with the exception of the transmembrane mutants L89P and I105R (3, 11) . The few pathogenic rBAT mutants which have been examined showed reduced or absent transport activity (8, 12, 13) . For the M467T and M467K mutations expressed in Xenopus oocytes, a trafficking defect was suggested, although function was recovered with higher protein expression, specially for the M467T mutant (12) , raising doubts about the situation in vivo. Only the R365W mutation has been expressed in a mammalian cell system and its traffic was also impaired (8) . However, the mechanism underlying these putative trafficking defects has not been addressed.
Here we report the basic features of the biogenesis of the rBAT-b 0,þ AT heterodimer in mammalian cells. We show that, without b 0,þ AT, rBAT is an ERAD (Endoplasmic Reticulum-Associated Degradation) substrate. Maturation of the rBAT-b 0,þ AT heterodimer requires interaction with the calnexin chaperone system, suggesting that folding of rBAT is not completed before assembly. We compare the fate of wild-type and type I cystinuria rBAT mutants L89P, T216M, R365W, M467K and M467T, with or without wildtype b 0,þ AT. T216M and M467T are the most common rBAT missense mutations, representing 6.4 and 26.4% of the alleles, respectively, of the International Cystinuria Consortium (3) . The transmembrane domain L89P mutant is assembly-defective, but not folding-defective. The extracellular domain rBAT mutants are degraded after efficient assembly with b 0,þ AT, indicating misfolding, but not assembly impairment.
RESULTS
Our aim was to examine the early biogenesis of wild-type human rBAT, b 0,þ AT and the rBAT-b 0,þ AT heterodimer and compare it with type I cystinuria rBAT mutants. HeLa and MDCK cells are good models to study these proteins (7 -10,14,15) . We used previously documented stable MDCK cell lines expressing wild-type rBAT, b 0,þ AT or both proteins together (9) . Only cells co-expressing rBAT and b 0,þ AT elicited cystine transport activity (9) .
Unassembled rBAT is an ERAD substrate
We set-up pulse-chase experiments followed by immunoprecipitation with specific antibodies [(6,15) and see Materials and Methods] directed against N-terminal peptides of rBAT and b 0,þ AT. In MDCK cells expressing only rBAT, this protein ran as a 90 kDa endoglycosidase-H sensitive band (consistent with its intracellular localization) (7, 8) , which, after a lag phase of 1 h, disappeared with a half-life of t 1/2 ¼ 54 + 4 min (Fig. 1) . In contrast, in MDCK cells expressing only b 0,þ AT, more than 60 and 30% of the pulse-labeled 40 kDa band of b 0,þ AT was detected after 8 and 24 h of chase, respectively (data not shown). We further characterized rBAT degradation. The proteasome inhibitors MG132 (Fig. 1) and lactacystin (not shown) delayed degradation, and so did the ER-mannosidase inhibitor dMNJ (Fig. 1) . Therefore, rBAT disposal is mediated, at least in part, by the proteasome and ER-mannosidase-dependent ERAD pathway (16, 17) . The lag phase suggests that rBAT is initially retained in the calnexin chaperone system (16) . Castanospermine inhibits glucose trimming mediated by the ER-glucosidases I and II (see the mobility shift of the rBAT band in Fig. 1 ), avoiding the generation of monoglucosylated N-glycans required for interaction with calnexin/calreticulin. The drug accelerated disposal (Fig. 1 , see the chase point 2 h), suggesting that interaction with the calnexin chaperone system delays rBAT degradation (16) . However, the lag phase was not reduced (Fig. 1 , see the chase point 1 h). Neither the lysosomal degradation inhibitor leupeptin nor the secretory pathway inhibitor brefeldin A had any effect on rBAT disposal (not shown). S-Met/Cys and chased with excess Met/Cys up to 4 h. Equivalent amounts of radioactivity incorporated into protein were immunoprecipitated with the anti-rBAT antibody. The precipitates were run under reducing conditions. The coreglycosylated rBAT band (rBAT c , 90 kDa) is observed. dMNJ (1 mM) and castanospermine (Cast., 1 mM) were present during all the experiment, whereas MG132 (30 mM) was added immediately after the pulse. The white arrow points out the effect of castanospermine on rBAT mobility, due to the inhibition of glucose trimming. Representative experiments are shown. (B) The quantifications (mean+SEM) of at least three independent experiments for each condition are shown. The value at each point of the chase was divided by the value at point zero, which was set to 100. Fig. 2A) . Immediately after the pulse, rBAT ran as a 90 kDa endoglycosidase H sensitive band under reducing conditions (7, 8) (Fig. 2A, þDTT panel) . This band co-precipitated with the anti-b 0,þ AT antibody, indicating that assembly took place within the ER and that it was a fast event ( Fig. 2A; þDTT panel, anti-b 0,þ AT IP, time zero lane). Assembly was mediated by a disulfide bridge ( Fig. 2A; 2DTT panel; the 135 kDa heterodimer band). Most of the labeled rBAT was co-precipitated with the anti-b 0,þ AT antibody ( Fig. 2A ; compare the rBAT bands with both immunoprecipitating antibodies in the þDTT panel). Consistently, rBAT was mainly found in the 135 kDa band ( Fig. 2A, 2DTT panel, anti-rBAT IP, time zero lane). During the chase, virtually all rBAT matured to a 96 kDa endoglycosidase H resistant band (7, 8) in a precursor-product fashion ( Fig. 2A, þDTT panel) . The maturation half-time was 1 h. Maturation of the heterodimer could also be observed ( Fig. 2A, 2DTT panel) . In spite of the similar amounts of rBAT detected with anti-rBAT and anti-b 0,þ AT antibodies, a stronger b 0,þ AT signal was seen with anti-b 0,þ AT ( Fig. 2A, þDTT panel) , indicating that much of the precipitated b 0,þ AT is not associated with rBAT, and that b 0,þ AT is present in great excess over rBAT. Moreover, the signal of the co-precipitated b 0,þ AT was much less intense than the rBAT signal, suggesting that newly synthesized rBAT was associated mainly with unlabeled b 0,þ AT ( Fig. 2A; anti-rBAT IP, þDTT panel). The group of Verrey observed a similar scenario (7) .
Next, we used castanospermine to examine the relevance of glucose trimming in assembly and maturation of rBAT-b 0,þ-AT (Fig. 2B) . When added during all the experiment, labeled rBAT molecules remained untrimmed (Fig. 2B , Cast. all; see the mobility shift). Inhibition of glucose trimming did not affect assembly of the heterodimer via a disulfide bridge (Fig. 2B , Cast. all, and data not shown), and did not induce degradation of rBAT (compare with Fig. 1 , Cast.). When castanospermine was added only during the chase (Fig. 2B , Cast. chase), no labeled untrimmed rBAT molecules were detected. In these conditions, we can measure the effect of inhibition of the glucosidase II-mediated trimming of the last glucose of N-glycans. This trimming facilitates dissociation of glycoproteins from calnexin/calreticulin (18) . Maturation of rBAT was delayed ( Fig. 2B ; observe the persistence of the endoglycosidase H sensitive rBAT band in the Cast. chase compared to the Control group), suggesting that the folding of rBAT is not complete before assembly of both subunits, and that it is facilitated by the calnexin chaperone system.
Type I cystinuria rBAT mutants are trafficking-defective
We used transient transfections in HeLa cells to study the biogenesis of type I cystinuria rBAT mutants localized either to the transmembrane or the TIM-barrel domains (Fig. 3A) . We have already used these cells to analyze the transport activity of the rBAT-b 0,þ AT heterodimer, its functional and structural units, and to report initial data on the R365W rBAT mutant (8, 10, 15) .
We confirmed the main results obtained in MDCK cells. In the absence of b 0,þ AT, rBAT was degraded, after a lag phase of 2 h, with a half life of t 1/2 ¼ 106 + 18 min, and degradation was at least in part mediated by the proteasome (Supplementary Material, Figure A) . We monitored assembly of rBAT and b 0,þ AT with transfection conditions which allow that almost all pulse-labeled rBAT co-precipitates with the anti-b 0,þ AT antibody (see Materials and Methods). The results were also comparable to MDCK cells. The endoglycosidase H resistant rBAT band was detected as a smear just above the endoglycosidase H sensitive band (Supplementary Material, Figure B and also Fig. 8 ). For this reason, maturation was followed directly with endoglycosidase H assays. After 8 h, all the pulse-labeled rBAT had complex N-glycosylation. The maturation half-time was 2 h (Supplementary Material, Figure B ). Inhibition of glucose trimming with castanospermine did not disturb assembly (not shown).
We transfected wild-type rBAT and type I cystinuria rBAT mutants in the presence of b 0,þ AT in HeLa cells and measured cystine transport. Only the L89P mutant showed a significant transport function (Fig. 3B ). Loss of function was not due to (6, 10) . This band was not detected in the mutants (with the exception of the L89P mutant and, in some experiments, the M467T mutant), suggesting failure to oligomerize (Fig. 4C) . We measured directly the amount of heterotetrameric rBAT-b 0,þ AT by blue native-PAGE followed by western blot, where [rBAT-b 0,þ AT] 2 runs at 500 kDa (10). We detected this band in the wild type and also in L89P, but at much lower amounts. Even less heterotetramer was present in the R365W and M467T lanes (Fig. 5) . All mutants were detected as aggregates (operationally defined as material that did not enter the stacking gel and/or that ran as a smear at the top of the running gel), with the exception of the M467T. We suggest that these aggregates contain both unassembled rBAT and single heterodimers, since: (i) bands with a size consistent with these species are not detected in blue native gels [data not shown and (10)]; (ii) they are observed in SDS -PAGE western blots (Fig. 4C) ; and (iii) unassembled rBAT is also seen as aggregates in blue native gels ( Fig. 5 ; see the asterisk). Interestingly, b 0,þ AT expressed alone was also detected as aggregated material in blue native gels (not shown). Assembly and oligomerization might dissolve rBAT and b 0,þ AT aggregates [which contain functional b 0,þ AT (9)], similar to the association of the chaperone Shr3p with the General Amino acid Permease from yeast (19) .
The L89P mutant assembles inefficiently with b 0,1 AT
We seek to find the molecular mechanism for the trafficking defects. We examined the degradation kinetics of the different rBAT species in the absence of b 0,þ AT and found no significant differences between the wild type and the mutants (Fig. 6 ). Notice that there is no mobility change in the T216M mutant (Fig. 6 , the asterisks). T216 lies in an N-glycosylation consensus site. The result indicates that this site is not used in vivo. The structural alignment of rBAT with the X-ray structure of the extracellular domain of the rBAT homologue 4F2hc shows that T216 is an internal residue located very close to the putative active cleft, explaining why this site is not N-glycosylated (20) . Next, we measured the assembly of wild-type and mutant rBAT with b 0,þ AT. Under our experimental conditions, more than 80% of the rBAT and b 0,þ AT expressed is immunoprecipitated with the specific antibodies (not shown). We compared the amounts of pulse-labeled rBAT immunoprecipitated by the anti-rBAT antibody with that co-precipitated by the anti-b 0,þ-AT antibody, under reducing conditions (Fig. 7A) . In HeLa cells, there is a great excess of b 0,þ AT over rBAT and most of the labeled rBAT is associated with unlabeled b 0,þ AT (data not shown), as in MDCK cells (Fig. 2A) . Therefore, under non-reducing conditions most of the radioactivity associated with the 135 kDa heterodimer band comes from labeled rBAT molecules. We obtained another estimation of assembly efficiency by comparing the 90 kDa band with the 135 kDa band in anti-rBAT immunoprecipitates under nonreducing conditions (Fig. 7B ). Both estimations indicated that only the L89P mutation had an assembly defect, because only between 10 and 30% of the labeled L89P mutant did heterodimerize with b 0,þ AT.
rBAT mutants of the TIM-barrel are degraded after assembly with b 0,1
AT
We followed the fate of wild-type and mutant rBAT in the presence of b 0,þ AT. A decay of the rBAT signal co-precipitated with the anti-b 0,þ AT antibody was observed for the T216M, R365W, M467K and M467T mutants (Fig. 8 and data not shown), indicating that the TIM-barrel mutants of rBAT are directed for disposal after assembly with b 0,þ AT. Endoglycosidase H assays confirmed that no maturation of rBAT mutants occurred during the chase (data not shown). In the case of the L89P mutant, we were able to detect low amounts of heterodimer, which remained stable throughout the chase ( Fig. 9 ; compare with wild-type and M467T heterodimers). These results suggest that mutants of the TIM-barrel domain of rBAT either delay or disrupt post-assembly folding of the rBAT extracellular domain. In striking contrast, the transmembrane domain L89P mutation may affect only the assembly step.
DISCUSSION

Biogenesis of the wild-type transporter
We measured for the first time the turnover rates and maturation half-times of the human subunits of the system b 0,þ -like, rBAT and b 0,þ AT, expressed alone or together. We show that unassembled rBAT is an ERAD glycoprotein substrate with a characteristic kinetic behavior: a lag phase, where unassembled rBAT may wait for b 0,þ AT while being retained by chaperones, followed by a degradation phase (16, 21, 22) . Contrary to other ERAD glycoprotein substrates (16, 23) , the retention was not by-passed by inhibition of glucose trimming in MDCK cells. In contrast, preliminar results show that castanospermine decreases the lag phase and accelerates the degradation phase of rBAT in HeLa cells (data not shown). We could only speculate about the difference between the two cell types. It is likely that the order and the kinetics of interactions between distinct chaperone complexes and rBAT during the lag phase are not the same. The most relevant interaction (related to degradation) between the calnexin chaperone system and rBAT during the lag phase may occur later in MDCK cells as compared with HeLa cells.
rBAT degradation is blocked by heterodimerization in the ER. This step is fast. Some labeled rBAT associates with b 0,þ AT after a 2.5 min pulse (not shown). This time is within the range needed to synthesize full-length rBAT (24) , suggesting that it can assemble co-translationally with already synthesized b 0,þ AT. Assembly might be independent of the calnexin chaperone system, as it is not impaired by the inhibition of the formation of monoglucosylated N-glycans. In contrast, preventing the deglucosylation of monoglucosylated N-glycans (which slows dissociation of glycoproteins from calnexin/calreticulin), delays maturation of rBAT-b 0,þ AT (Fig. 2B ). This result indicates that maturation of rBAT within the heterodimer depends on interactions with the lectins. We propose that there are some post-assembly folding steps of the extracellular domain of rBAT, which are 0,þ AT folding seems to be independent of rBAT, because it is functional in its absence (9) . Our data are compatible with models proposed for other oligomeric protein complexes, such as potassium channels and acetylcholine receptors, where biogenesis proceeds through interspersed folding and assembly steps (25, 26) .
Biogenesis of type I cystinuria rBAT mutants
Wild-type biogenesis provides the framework to study type I cystinuria rBAT mutations. In Xenopus oocytes, the M467T, M467K and T216M mutants showed reduced transport activity (12, 13) . Amino acid uptake increased and even reached wildtype levels upon higher expression (12) , raising doubts about the situation in vivo. Instead, the R365W mutant was not functional in HeLa cells [(8) and Fig. 3B ]. Here we demonstrate that the mutants tested lack function in human cells and none of them acquires complex N-glycosylation (but see below). Therefore, the absence of transport activity is primarily due to strong trafficking defects.
The heterotetramer [rBAT-b 0,þ AT] 2 is the structural unit of this transporter at the plasma membrane and the single heterodimer is the functional unit (10). The small, but significant, transport measured in the L89P mutant correlates with the few heterotetramers and mature L89P molecules detected. The even lower levels of M467T heterotetramers and mature molecules may be not enough to detect significant uptake ( Figs 4B and 5) . In fact, all the mutants tested fail, to different extents, to form stable heterotetramers. They are instead detected as aggregates in blue native gels (with the exception of M467T). Our solubilization conditions may allow resolution only of heterotetramers, but not heterodimers or monomers. Aggregation could be also due to the presence of high molecular weight complexes containing ER-resident chaperones or ERAD machinery (27, 28) . In any case, the aggregation suggests a folding and/or assembly defect that hinders formation of mutant heterotetramers. Dimerization of the heterodimer may be needed for ER-exit. Oligomerization can be one of the final quality control steps of the biogenesis of rBAT-b 0,þ AT, as shown for other proteins (29, 30) . From the mutations studied here, L89P is in the transmembrane domain and the rest lie in the (b/a) 8 TIM-barrel of the AT antibody. The precipitates were run under reducing conditions. The results of a representative experiment with the wild-type and the M467K mutant are presented. The wildtype and M467K samples are from the same experiment and have been processed in parallel (although in two different gels). The two dried gels were exposed simultaneously in the same intensifying screen. The quantification of the rBAT signal co-precipitated with the anti-b 0,þ AT antibody is shown. This signal corresponds to the sharp endoglycosidase H-sensitive band together with the diffuse endoglycosidase H-resistant rBAT species appearing only at 2, 5 and 8 h chase points in the wild type (see also Supplementary Material, Figure B) . Data are the mean+SEM of at least three independent experiments for each rBAT species. extracellular domain [(20) and Fig. 3A] . We do not know how these mutations affect the folding and/or assembly of rBAT. However, they do not lead to a new phenotype in the absence of b 0,þ AT, since unassembled wild-type and mutant rBAT disappear with similar kinetics (Fig. 6 ). There are other examples of this behavior, as K IR 6.2 mutations of K ATP channels when expressed without the sulfonylurea receptor (SUR) subunit (31) . Only co-expression with b 0,þ AT discriminates between wild-type rBAT and mutants.
The mutants fail to exit the ER and are directed to disposal, strongly suggesting a defect in early biogenesis, like many other mutant proteins in the secretory pathway (17, 32) . . This may be due to overexpression. However, the stability and functionality of the L89P heterodimers suggest that, in contrast to the TIMbarrel mutants (see below), the L89P mutation does not cause misfolding.
The TIM-barrel mutants show a trafficking defect of different origin. They assemble efficiently with b 0,þ AT, but are subsequently degraded, suggesting misfolding of the extracellular domain. It is interesting also to compare the ratio 135/250 kDa bands between wild-type, L89P and M467T mutants in Figure 4C . This ratio is similar for the wild-type and the L89P mutant, but it clearly differs from that of the M467T mutant. This suggests that, once the heterodimer is formed, both the wild-type and the L89P mutant can readily form the heterotetramer. In contrast, for the M467T mutation, only a few heterodimers can oligomerize, arguing again for a folding defect. Therefore, at least two different classes of pathogenic rBAT mutants exist: assembly defective (L89P) and folding-defective (TIM-barrel mutants). At our level of analysis, these two classes are mutually exclusive, but lead to the same type I cystinuria phenotype. It is unlikely that the correlation between the position of the mutants within the rBAT protein and their molecular effects is just a mere coincidence.
Summary model
The data are consistent with a minimal working model for the biogenesis of the rBAT-b 0,þ AT transporter. Fast interactions of the N-terminal and transmembrane domains of rBAT with folded b 0,þ AT determine formation of the heterodimer, which is impaired in the L89P mutant. Assembly with b 0,þ AT blocks rBAT degradation. These early steps do not require the calnexin chaperone system. After assembly, the rBAT extracellular domain folds within that chaperone system. Heterotetramerization proceeds immediately after completion of rBAT folding, or interspersed within the final folding steps. Only the heterotetramers exit the ER to the Golgi complex. Mutations of the extracellular domain of rBAT disrupt or delay the post-assembly folding of rBAT, hindering stable oligomerization and leading to its degradation.
MATERIALS AND METHODS
Reagents and antibodies
Reagents were purchased from Sigma unless otherwise indicated. Pro-mix l-[ 0,þ AT and rBAT are described elsewhere (6, 15) .
cDNA constructs
The vectors for mammalian cell expression of human rBAT and b 0,þ AT have been described elsewhere (15) . The construction of the R365W, M467T and M467K rBAT mutants is detailed in (8, 12) . To express the M467T and M467K rBAT mutants in mammalian cells, the cDNAs in pSPORT were removed with EcoRI and XbaI and cloned into pCDNA3 cut with the same enzymes. The L89P and T216M mutants were obtained by site-directed mutagenesis (QuickChangeTM, Stratagene) of pCDNA3-rBAT, using the mutagenic oligonucleotides (only sense oligonucleotides are shown): 5 0 -ATACCTCGGGAGATCCCCTTCTGGCTCACAGTG-3 0 , and 5 0 -CATACCAAACCACATGAGTGATAAACATATTT GGTTTC-3 0 , respectively. All mutations were confirmed by DNA sequencing using the d-Rhodamine dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer Applied Biosystems). The sequence reactions were analysed with an Abi Prism 377 DNA Sequencer.
Cell culture and transfection
MDCK-IIJ and HeLa cells were grown in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal calf serum (heat-inactivated), 100 U/ml penicillin (Gibco) and 0.1 mg/ml streptomycin (Gibco), at 378C in a humidified atmosphere containing 5% CO 2 . Stably transfected MDCK-derived cell lines (9) were supplemented with the appropriate selection agent (400 mg/ml geneticin and/or 100 mg/ml hygromycin B). Calcium phosphate transient transfection of HeLa cells was performed as described (12, 15) . The efficiency of transfection was above 70% in all experiments. For transient transfections, 10 cm diameter plates were incubated with a mixture of DNA containing 2 mg of pEGFP (green fluorescence protein; Clontech), 6 mg of pCDNA3-rBAT (wild-type or the different mutants) and 12 mg of pCDNA3-b 0,þ AT as described (12, 15) . In these conditions, more than 80% of the labeled wild-type rBAT molecules in pulse-chase studies were assembled with b 0,þ AT (data not shown). When rBAT or b 0,þ AT were transfected alone, 12 or 6 mg of pCDNA3 were added, respectively.
Membrane preparation, SDS -PAGE, western blot and blue native gel electrophoresis
We have published detailed procedures for these methods elsewhere (6, 10) . Protein quantitation was performed with the BCA method (Pierce).
Transport measurements
Influx rates of 50 mM L-[ 3 H]arginine (ARC) and 20 mM L-[ 35 S]cystine (Amersham) in transfected HeLa cells were performed as described (9, 15) .
Endoglycosidase H assay
The enzyme was obtained from New England Biolabs and was used following the manufacturer protocol.
Pulse-chase and immunoprecipitation protocols
Cells were transfected and seeded in 3.5 cm diameter plates at 60-70% confluence. The following day cells were incubated for 30 min in pre-warmed L-Methionine/L-Cystine free media containing 10% dialyzed FBS. Subsequently, cells were labeled for 15 (MDCK) or 30 min (HeLa) with a mixture of [
35 S]methionine/cysteine (120 mCi/ml) and, after removal of the labeling media, incubated with pre-warmed media supplemented with 5 mM unlabeled L-methionine/ L-cysteine. At the indicated times, cells were washed twice with cold phosphate-buffered saline (PBS) and once with cold PBS containing 20 mM N-ethylmaleimide for 5 min. Cells were collected and lysed on a rotating wheel in 0.2 ml of NET buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4, 0.5% NP-40) with the protease inhibitors aprotinin, leupeptin, phenylmethylsulfonyl fluoride, and pepstatin, and 20 mM NEM. After 30 min at 48C, a postnuclear supernatant was obtained by 10 min of 10 000 g centrifugation at 48C. Inhibitors [25 mM lactacystin, 30 mM MG132, 1 mM castanospermine (Cast.), 1 mM 1-deoxymannojirimycin (DMNJ), 10 mg/ml Brefeldin A, and 200 mg/ml leupeptin] and control vehicles were included from the beginning of the starving period to the end of the chase, except for castanospermine in some experiments, and for MG132, which was added after the end of the pulse. All inhibitors were from Calbiochem.
Immunoprecipitations were performed from equivalent amounts of radioactivity incorporated into proteins, by adding an equal volume of immunoabsorbent buffer (200 mM H 3 BO 3 , 50 mM Na 2 B 4 O 7 , 150 mM NaCl, 1% NP-40 and 0.1% ovalbumin, pH 8.3) with the same protease inhibitors as the lysis buffer, and polyclonal antibodies to rBAT or b 0,þ AT, in combination with protein A-Sepharose. Precipitates were washed four times with borate-NaCl buffer (0.5% NP-40, 0.3 M NaCl, 25 mM Na 2 B 4 O 7 and 0.1 M H 3 BO 4 , pH 8.3) and twice with 40 mM HEPES, pH 8. Samples were run on SDS -PAGE under reducing or non-reducing conditions. Gels were stained with Coomassie brilliant blue to control for precipitating antibodies, dried and put on an intensifying screen for quantification with a Phosphoimager Typhoon 8600 (Molecular Dynamics).
Preliminar immunoprecipitation experiments were performed to control for the efficiency and the specificity of the immunoprecipitating antibodies. In our experimental cell system and pulse-chase conditions, the antibodies almost quantitatively immunoprecipitated all the pulse-labeled rBAT and b 0,þ AT molecules (more than 80%; data not shown). Co-precipitation of rBAT and b 0,þ AT with the anti-b 0,þ AT antibody, and of b 0,þ AT and rBAT with the antirBAT antibody did not occur when lysates from cells expressing rBAT alone and b 0,þ AT alone were mixed before immunoprecipitation (Supplementary Material, Figure C) .
Data analysis
The relative intensities of the labeled bands were determined using phosphorimaging, as follows: each band was outlined by a rectangle (as tightly-fitting to the band as possible) and a rectangle of identical size was drawn in the closest area without any band in the lane. The relative positions of band and background rectangles were maintained within the experiment and among similar experiments. The value for each rectangle was calculated using the Local Average Background Correction of the ImageQuant software. The final value of the band was the difference between the value of the rectangle band and the value of the rectangle background. The data were plotted as intensity values of the fraction remaining obtained by dividing by the zero time value, if not otherwise indicated. The decay data were fitted to an initial time in a Plateau followed by a single exponential function. The Plateau period and the half-life results are given as mean+SEM. The maturation values were fitted to a four-parameter logistic equation (with bottom and top values set of 0 and 100, respectively).
